Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
2 Incredible Stocks to Buy With Less Than $25
10:00am, Tuesday, 04'th Apr 2023
Exelixis develops cancer drugs, a strategy that should continue to breed success. Adyen helps facilitate e-commerce across borders and is investing in its future.
Exelixis Targeted as Activist Farallon Capital Partners Reveals 7.2% Holding
10:20pm, Tuesday, 21'st Mar 2023
It has been an eventful start to the week for investors of genomics-based drug discovery outfit Exelixis (US:EXEL), after the company announced a share buyback worth $550 million pre-market and receiv
Why Exelixis Stock Leaped More Than 4% Higher Today
07:11pm, Monday, 20'th Mar 2023
The biotech announced a shareholder-pleasing bit of financial engineering. This will total as much as $550 million by the end of this year.
Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit
04:05pm, Monday, 13'th Mar 2023
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will provide a corporate overview at the 2023 Guggenheim Healthy Altitudes Summit on Thursday, M
2 Stocks to Buy With Less Than $20
10:07am, Friday, 10'th Mar 2023
Exelixis' exciting oncology platform can lead to new products and higher revenue. Snap's popularity among younger users remains a major long-term tailwind.
Exelixis' (EXEL) Cabozantinib Combo Study Fails to Meet Goal
02:18pm, Monday, 06'th Mar 2023
Exelixis' (EXEL) combo-drug study for kidney cancer fails to meet the primary endpoint of progression-free survival (PFS).
Exelixis Inc.: Cancer Crusader With A Bright Future
03:10am, Tuesday, 28'th Feb 2023
Exelixis has strong revenue growth and a positive outlook. Past success with a growing industry ensures demand for its products.
Exelixis (EXEL), Sairopa Obtains IND Clearance for ADU-1805
01:33pm, Tuesday, 14'th Feb 2023
Exelixiss' EXEL) partner Sairopa gets FDA clearance for its IND application for the oncology drug ADU-1805, a potential best-in-class monoclonal antibody for adults with advanced solid tumors.
2 Biotech Stocks You Can Buy and Hold for the Next Decade
09:00am, Sunday, 12'th Feb 2023
These companies could grow in prominence in the coming years.
Exelixis (EXEL) Q4 Earnings Top, Revenues Beat on Cabometyx
01:33pm, Wednesday, 08'th Feb 2023
Exelixis (EXEL) beats earnings and sales estimates for the fourth quarter due to increased Cabometyx sales volume.
Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics
07:32am, Wednesday, 08'th Feb 2023
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended December 2022, but it may be worthwhile to compare some of its key metrics to Wall Street esti
Exelixis (EXEL) Q4 2022 Earnings Call Transcript
06:00am, Wednesday, 08'th Feb 2023 The Motley Fool
EXEL earnings call for the period ending December 31, 2022.
Exelixis (EXEL) Reports Q4 Loss, Tops Revenue Estimates
10:55pm, Tuesday, 07'th Feb 2023 Zacks Investment Research
Exelixis (EXEL) delivered earnings and revenue surprises of 40% and 1.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Exelixis, Inc. (EXEL) Q4 2022 Earnings Call Transcript
08:48pm, Tuesday, 07'th Feb 2023
Exelixis, Inc. (NASDAQ:EXEL ) Q4 2022 Results Conference Call February 7, 2023 5:00 PM ET Company Participants Susan Hubbard - EVP, Public Affairs and IR Mike Morrissey - President and CEO Chris Senne
Exelixis (EXEL) Reports Q4 Loss, Tops Revenue Estimates
07:34pm, Tuesday, 07'th Feb 2023
Exelixis (EXEL) delivered earnings and revenue surprises of 40% and 1.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
